Skip to content

History

During late 1990’s, Marianne Jensen Waern worked at the Swedish University of Agricultural Science in Uppsala on a project to prevent pneumonia among foals. She came into contact with Kristina Nilsson Ekdahl and Bo Nilsson at Uppsala University, and a close collaboration on immunity ensued. The innate immune system is necessary for our survival. Kristina and Bo have spent decades on researching this part of the immune system. This research has resulted in important findings concerning so called thromboinflammation and how the immune system is activated in connection to transplantations among other things. In 2010 Yuji Teramura became guest Professor at Uppsala University. In his research, Yuji managed to create a product that can protect cells from thromboinflammation.

Through combined efforts, the scientists at the time wanted to research whole organs. In 2012, surgeon Alireza Biglarnia carried out a proof-of-concept study on iCM012 in pigs with promising results. Significant grants then made it possible to deepen research regarding iCM012 and methods to tackle thromboinflammation were developed. In 2018, the company iCoat Medical was founded with the goal of improving outcomes of kidney transplants. Since start the company has grown and added several engaged doctors and scientists and other staff. The first clinical study presented initial results in 2023 and was successfully completed in 2024.

1980

Vast research on the innate immune system.

2005

First prototype of the future product iCM012 is developed to protect cells.

2012

Proof of Concept for iCM012 is established for pigs

2013-2018

Several studies are carried out on kidney transplants in pigs.

2018

Safety studies are successfully carried out in rodents and iCoat Medical AB is founded.

2019

Patent application is filed for iCM012.

2020

Patent application is filed for iCM020.

2021

The company’s First In Human study is initiated and in parallel preclinical studies begin on heart transplants in pigs.